Table 1 Demographic and clinical characteristics of patients identified in the French PharmacoVigilance Database with type 2 diabetes.

Age (years)

67.2 (13.4)

[19-97]

63.3 (14.2)****

[32-87]

67.5 (13.8)

[19-97]

Gender (men)

1155 (49.7)

92 (57.1)

1063 (49.8)

Cardiovascular comorbidities

Cardiac arrhythmia

128 (5.58)

8 (5)

120 (5.6)

Cardiac insufficiency

248 (10.81)

9 (5.6)*

239 (11.2)

Hypertension

596 (25.97)

33 (20.5)

563 (26.4)

Metabolic disorders

621 (27.06)

30 (18.7)*

591 (27.7)

Angina pectoris

154 (6.71)

6 (3.7)

148 (6.9)

Atherosclerosis

6 (0.26)

0 (0)

6 (0.28)

Obesity

76 (3.31)

10 (6.2)*

66 (3.1)

Heart valve disorders

7 (0.31)

1 (0.6)

6 (0.28)

Renal disorders

62 (2.7)

2 (1.2)

60 (2.8)

Drugs used for type 2 diabetes

Sulfamides

1227 (53.46)

44 (27.33)****

1183 (55.43)

Alpha glucosidase inhibitor

207 (9.02)

4 (2.48)**

203 (9.5)

Glinides

192 (8.37)

6 (3.7)*

186 (8.7)

Metformin

900 (39.22)

58(36)

842 (39.5)

Benfluorex

227 (9.89)

4 (2.5)**

223 (10.45)

Insulin

115 (5.01)

4 (2.94)

111 (5.20)

Cardiovascular drugs

Diuretics

627 (27.32)

34 (21.1)

593 (27.7)

ACE inhibitors

456 (19.87)

20 (12.4)*

436 (20.4)

Angiotensin II inhibitors

339 (14.77)

23 (14.3)

316 (14.8)

Digitalics

105 (4.58)

3 (1.9)

102 (4.8)

Betablockers

300 (13.07)

9 (5.6)**

291 (13.6)

Calcium inhibitors

321 (13.99)

16 (9.94)

305 (14.3)

Trinitrin

48 (2.09)

3 (1.9)

45 (2.1)

Amiodarone

103 (4.49)

2 (1.24)*

101 (4.73)

Central antihypertensive drugs

73 (3.18)

5 (3.1)

68 (3.2)

Antiarrythmia drugs

25 (1.09)

1 (0.6)

24 (1.12)

Other drugs

Steroidal and Non Steroidal Anti-Inflammatory Drugs

232 (10.1)

8 (4.96)*

224 (10.5)

Statins

403 (17.56)

17 (10.6)*

386 (16.8)

Fibrates

142 (6.19)

7 (4.35

135 (6.3)